Key result
Single nucleotide polymorphisms in ADIPOQ, ADIPOR1, and ADIPOR2 genes, particularly SNP +45 and SNP +276, may modify the risk of coronary artery disease in patients with type 2 diabetes mellitus.
Why the study?
Patients with T2DM are at increased risk of CAD, and adiponectin and its receptor gene polymorphisms may link metabolic and cardiovascular disease.
Do single nucleotide polymorphisms in adiponectin and its receptors' genes increase the risk of coronary artery disease in patients with type 2 diabetes mellitus?
Do single nucleotide polymorphisms in adiponectin and its receptors' genes increase the risk of coronary artery disease in patients with type 2 diabetes mellitus?
Genetic variants in adiponectin and its receptors may serve as novel molecular markers for identifying type 2 diabetic patients at especially high risk for coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Adiponectin assessment may refine CAD risk stratification in T2DM; leaves open whether targeting it alters outcomes.
Szydełko et al. (2021) conducted a review in Type 2 diabetes mellitus and coronary artery disease. Single nucleotide polymorphisms in adiponectin and its receptors' genes vs. Patients without these specific genetic variants was evaluated on Risk of coronary artery disease. Single nucleotide polymorphisms in ADIPOQ, ADIPOR1, and ADIPOR2 genes, particularly SNP +45 and SNP +276, may modify the risk of coronary artery disease in patients with type 2 diabetes mellitus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: